nach oben

Erschienen in:

13.05.2024 | Rektumkarzinom | CME

Therapiestrategien beim Rektumkarzinomrezidiv

verfasst von: Sophia Dietz, Johannes Fritzmann, Anne Weidlich, Klaus-Dieter Schaser, Jürgen Weitz, Dr. med. Johanna Kirchberg

Erschienen in: Die Chirurgie | Ausgabe 6/2024

Einloggen, um Zugang zu erhalten

Zusammenfassung

Multimodale Therapieansätze mit neoadjuvanter Strahlen- und Chemotherapie gefolgt von onkologischer und totaler mesorektaler Resektion (TME) haben die Rezidivrate selbst bei lokal fortgeschrittenen Rektumkarzinomen deutlich reduziert. Dennoch entwickeln bis zu 10 % der Patienten ein Rezidiv. Die chirurgische R0-Resektion stellt bei der Behandlung eines lokal rezidivierten Rektumkarzinoms (LRRC) die einzige Chance auf Heilung dar. Aufgrund der durch Vorbehandlungen bzw. -operationen veränderten Anatomie und Physiologie des kleinen Beckens sowie der Lokalisation und Ausdehnung des Rezidivs erfolgt die Therapieentscheidung individualisiert und stellt weiterhin eine Herausforderung für das interdisziplinäre Team dar. Auch fortgeschrittene Tumoren mit Beteiligung benachbarter Strukturen können in ausgewiesenen Zentren durch multimodale Therapiekonzepte in potenziell kurativer Intention behandelt werden.

Palmer G et al (2007) A population-based study on the management and outcome in patients with locally recurrent rectal cancer. Ann Surg Oncol 14(2):447–454CrossRefPubMed

Martling, A.L., et al., Effect of a surgical training programme on outcome of rectal cancer in the County of Stockholm. Stockholm Colorectal Cancer Study Group, Basingstoke Bowel Cancer Research Project. Lancet, 2000. 356(9224): p. 93–6.

van Gijn W et al (2011) Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 12(6):575–582CrossRefPubMed

Jayne DG et al (2010) Five-year follow-up of the Medical Research Council CLASICC trial of laparoscopically assisted versus open surgery for colorectal cancer. Br J Surg 97(11):1638–1645CrossRefPubMed

(2018) Factors affecting outcomes following pelvic exenteration for locally recurrent rectal cancer. Br J Surg 105(6):650–657

Heriot and Kumar, Rectal cancer recurrence: factors and mechanisms. Colorectal Dis, 2000. 2(3): p. 126–36.

Heald, R.J., Total mesorectal excision. The new European gold standard. G Chir, 1998. 19(6–7): p. 253–5.

Kafka NJ, Enker WE (1999) Total mesorectal excision with autonomic nerve preservation: a new foundation for the evaluation of multi-disciplinary adjuvant therapy in the management of rectal cancers. Ann Chir 53(10):996–1002PubMed

Quirke P et al (2009) Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial. Lancet 373(9666):821–828CrossRefPubMedPubMedCentral

10.

Cercek A et al (2022) PD‑1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. N Engl J Med 386(25):2363–2376CrossRefPubMedPubMedCentral

11.

Schrag D et al (2023) Preoperative Treatment of Locally Advanced Rectal Cancer. N Engl J Med 389(4):322–334CrossRefPubMedPubMedCentral

12.

Ruppert R et al (2018) Oncological outcome after MRI-based selection for neoadjuvant chemoradiotherapy in the OCUM Rectal Cancer Trial. Br J Surg 105(11):1519–1529CrossRefPubMed

13.

Bahadoer RR et al (2021) Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol 22(1):29–42CrossRefPubMed

14.

Conroy T et al (2021) Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 22(5):702–715CrossRefPubMed

15.

Verheij FS et al (2023) Long-Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA Trial. J Clin Oncol p:Jco2301208

16.

Dijkstra EA et al (2023) Locoregional Failure During and After Short-course Radiotherapy Followed by Chemotherapy and Surgery Compared With Long-course Chemoradiotherapy and Surgery: A 5-Year Follow-up of the RAPIDO Trial. Ann Surg 278(4):e766–e772CrossRefPubMed

17.

Garcia-Aguilar J et al (2022) Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy. J Clin Oncol 40(23):2546–2556CrossRefPubMedPubMedCentral

18.

Heald RJ et al (2017) The Perfect Total Mesorectal Excision Obviates the Need for Anything Else in the Management of Most Rectal Cancers. Clin Colon Rectal Surg 30(5):324–332CrossRefPubMedPubMedCentral

19.

Leite JS et al (2011) Clinical significance of macroscopic completeness of mesorectal resection in rectal cancer. Colorectal Dis 13(4):381–386CrossRefPubMed

20.

Wichmann MW et al (2002) Results of long-term follow-up after curative resection of Dukes A colorectal cancer. World J Surg 26(6):732–736CrossRefPubMed

21.

Mirnezami, A., et al., Increased local recurrence and reduced survival from colorectal cancer following anastomotic leak: systematic review and meta-analysis. Ann Surg, 2011. 253(5): p. 890–9.

22.

Merkel S et al (2001) Locoregional recurrence in patients with anastomotic leakage after anterior resection for rectal carcinoma. Colorectal Dis 3(3):154–160CrossRefPubMed

23.

Wang S et al (2017) Adverse Effects of Anastomotic Leakage on Local Recurrence and Survival After Curative Anterior Resection for Rectal Cancer: A Systematic Review and Meta-analysis. World J Surg 41(1):277–284CrossRefPubMed

24.

Grosu S et al (2016) Differentiating locally recurrent rectal cancer from scar tissue: Value of diffusion-weighted MRI. Eur J Radiol 85(7):1265–1270CrossRefPubMed

25.

Ito K et al (1992) Recurrent rectal cancer and scar: differentiation with PET and MR imaging. Radiology 182(2):549–552CrossRefPubMed

26.

Plodeck V et al (2019) FDG-PET/MRI in patients with pelvic recurrence of rectal cancer: first clinical experiences. Eur Radiol 29(1):422–428CrossRefPubMed

27.

Gockel I et al (2018) Resection of recurrent rectal cancer. Chirurg 89(8):647–660CrossRefPubMed

28.

Lampe B et al (2021) Opportunities and Limitations of Pelvic Exenteration Surgery. Cancers (basel) 13(24)

29.

Lyell NJ et al (2019) The effect of preoperative nutritional status on postoperative complications and overall survival in patients undergoing pelvic exenteration: A multi-disciplinary, multi-institutional cohort study. Am J Surg 218(2):275–280CrossRefPubMed

30.

van Rees JM et al (2021) Impact of nutritional status and body composition on postoperative outcomes after pelvic exenteration for locally advanced and locally recurrent rectal cancer. Bjs Open 5(5)

31.

Bartoszko J et al (2019) Association of preoperative anaemia with cardiopulmonary exercise capacity and postoperative outcomes in noncardiac surgery: a substudy of the Measurement of Exercise Tolerance before Surgery (METS) Study. Br J Anaesth 123(2):161–169CrossRefPubMedPubMedCentral

32.

Kehlet H, Wilmore DW (2002) Multimodal strategies to improve surgical outcome. Am J Surg 183(6):630–641CrossRefPubMed

33.

Kehlet H (2008) Fast-track colorectal surgery. Lancet 371(9615):791–793CrossRefPubMed

34.

Kehlet H, Wilmore DW (2008) Evidence-based surgical care and the evolution of fast-track surgery. Ann Surg 248(2):189–198CrossRefPubMed

35.

van Zoggel D et al (2018) Preliminary results of a cohort study of induction chemotherapy-based treatment for locally recurrent rectal cancer. Br J Surg 105(4):447–452CrossRefPubMed

36.

Denost Q et al (2021) A phase III randomized trial evaluating chemotherapy followed by pelvic reirradiation versus chemotherapy alone as preoperative treatment for locally recurrent rectal cancer—GRECCAR 15 trial protocol. Colorectal Dis 23(7):1909–1918CrossRefPubMed

37.

McCarthy ASE et al (2020) Quality of life and functional outcomes following pelvic exenteration and sacrectomy. Colorectal Dis 22(5):521–528CrossRefPubMed

38.

van Kessel, C.S., et al., Improving Surgical Outcomes in Pelvic Exenteration Surgery: Comparison of Prone Sacrectomy With Anterior Cortical Sacrectomy Techniques. Ann Surg, 2023. 278(6): p. 945–953.

39.

Bloemendaal AL et al (2016) Double-barrelled wet colostomy formation after pelvic exenteration for locally advanced or recurrent rectal cancer. Colorectal Dis 18(11):O427–o431CrossRefPubMed

40.

Sahakitrungruang C, Atittharnsakul P (2012) Colonic flap with mucosa removed: a novel technique for pelvic reconstruction after exenteration of advanced pelvic malignancy. Tech Coloproctol 16(5):373–378CrossRefPubMed

41.

(2019) Pelvic Exenteration for Advanced Nonrectal Pelvic Malignancy. Ann Surg 270(5):899–905

42.

Waters PS et al (2019) Evolution of pelvic exenteration surgery—resectional trends and survival outcomes over three decades. Eur J Surg Oncol 45(12):2325–2333CrossRefPubMed

43.

Bogner A et al (2021) Pelvic exenteration for colorectal and non-colorectal cancer: a comparison of perioperative and oncological outcome. Int J Colorectal Dis 36(8):1701–1710CrossRefPubMedPubMedCentral

44.

Nakai, S., et al., Anorectal and bladder function after sacrifice of the sacral nerves. Spine (Phila Pa 1976), 2000. 25(17): p. 2234–9.

45.

Ozaki T, Hillmann A, Winkelmann W (1997) Surgical Treatment of sacrococcygeal chordoma. J Surg Oncol 64(4):274–279CrossRefPubMed

46.

Brown, K.G.M., et al., Sciatic and Femoral Nerve Resection During Extended Radical Surgery for Advanced Pelvic Tumours: Long-term Survival, Functional, and Quality-of-life Outcomes. Ann Surg, 2021. 273(5): p. 982–988.

47.

Harji DP et al (2023) Short-term outcomes of health-related quality of life in patients with locally recurrent rectal cancer: multicentre, international, cross-sectional cohort study. Bjs Open 7(1)

48.

Westberg K et al (2018) Management and prognosis of locally recurrent rectal cancer—A national population-based study. Eur J Surg Oncol 44(1):100–107CrossRefPubMed

Titel: Therapiestrategien beim Rektumkarzinomrezidiv
verfasst von: Sophia Dietz
Johannes Fritzmann
Anne Weidlich
Klaus-Dieter Schaser
Jürgen Weitz
Dr. med. Johanna Kirchberg
Publikationsdatum: 13.05.2024
Verlag: Springer Medizin
Schlagwörter: Rektumkarzinom
Rektumkarzinom
Tumorchirurgie
Urologische Chirurgie
Magnetresonanztomografie
Wundheilungsstörung
Erschienen in: Die Chirurgie / Ausgabe 6/2024
Print ISSN: 2731-6971
Elektronische ISSN: 2731-698X
DOI: https://doi.org/10.1007/s00104-024-02087-w

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2024

Neoadjuvante Chemotherapie in retroperitonealen Sarkomen

eHealth in der Chirurgie

Digitale Applikationen in der Prähabilitation vor großen viszeralchirurgischen Operationen

Der digitale Operationssaal

Kurz- und Langzeitergebnisse nach minimal-invasiver Leberresektion bei solitären kleinen hepatozellulären Karzinomen

Verschlechterte Langzeitprognose infolge präoperativer Anämie vor allgemeinchirurgischen Eingriffen